| Year |
Citation |
Score |
| 2024 |
Yoon H, Savoy EA, Mesbahi N, Hendrickson AT, March GL, Fulton MD, Backer BS, Berkman CE. A PSMA-targeted doxorubicin small-molecule drug conjugate. Bioorganic & Medicinal Chemistry Letters. 129712. PMID 38521177 DOI: 10.1016/j.bmcl.2024.129712 |
0.359 |
|
| 2024 |
Dhull A, Wei J, Pulukuri AJ, Rani A, Sharma R, Mesbahi N, Yoon H, Savoy EA, Xaivong Vi S, Goody KJ, Berkman CE, Wu BJ, Sharma A. PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer. Nanoscale. PMID 38440933 DOI: 10.1039/d3nr06520k |
0.33 |
|
| 2023 |
Savoy EA, Olatunji FP, Fulton MD, Kesic BN, Herman JW, Romero O, Maniatopoulos M, Berkman CE. PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers. Bioorganic & Medicinal Chemistry Letters. 129573. PMID 38052377 DOI: 10.1016/j.bmcl.2023.129573 |
0.365 |
|
| 2022 |
Olatunji FP, Pun M, Herman JW, Romero O, Maniatopoulos M, Latoche JD, Parise RA, Guo J, Beumer JH, Anderson CJ, Berkman CE. Modular Smart Molecules for PSMA-Targeted Chemotherapy. Molecular Cancer Therapeutics. PMID 35999662 DOI: 10.1158/1535-7163.MCT-22-0160 |
0.314 |
|
| 2020 |
Talley TT, Chao CK, Berkman CE, Richardson RJ, Thompson CM. Inhibition of acetylcholinesterases by stereoisomeric organophosphorus compounds containing both thioester and p-nitrophenyl leaving groups. Chemical Research in Toxicology. PMID 32833441 DOI: 10.1021/Acs.Chemrestox.0C00236 |
0.332 |
|
| 2019 |
Ling X, Latoche JD, Choy CJ, Kurland BF, Laymon CM, Wu Y, Salamacha N, Shen D, Geruntho JJ, Rigatti LH, Windish HP, Langton-Webster B, Berkman CE, Anderson CJ. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 31321650 DOI: 10.1007/S11307-019-01404-8 |
0.461 |
|
| 2019 |
White DS, Choy CJ, Moural TW, Martin SE, Wang J, Gargaro S, Kang C, Berkman CE. Bis(benzoyl) phosphate inactivators of beta-lactamase C from Mtb. Bioorganic & Medicinal Chemistry Letters. PMID 31281019 DOI: 10.1016/J.Bmcl.2019.07.002 |
0.306 |
|
| 2018 |
Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, ... Berkman CE, et al. First-in-Human Phase I study of CTT1057, a Novel F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30464040 DOI: 10.2967/Jnumed.118.220715 |
0.412 |
|
| 2017 |
Choy CJ, Ling X, Geruntho JJ, Beyer SK, Latoche JD, Langton-Webster B, Anderson CJ, Berkman CE. (177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Theranostics. 7: 1928-1939. PMID 28638478 DOI: 10.7150/Thno.18719 |
0.475 |
|
| 2017 |
Aggarwal RR, Behr S, Seo Y, Gao K, Rahanfar V, Slater J, Blecha J, Langton-Webster B, Berkman C, Vanbrocklin H. First-in-human phase 1 PET study of CTT1057, a novel 18F-labeled imaging agent targeting prostate specific membrane antigen (PSMA) in prostate cancer. Journal of Clinical Oncology. 35: e16562-e16562. DOI: 10.1200/Jco.2017.35.15_Suppl.E16562 |
0.341 |
|
| 2017 |
Ziaei P, Geruntho JJ, Marin-Flores OG, Berkman CE, Grant Norton M. Silica nanostructured platform for affinity capture of tumor-derived exosomes Journal of Materials Science. 52: 6907-6916. DOI: 10.1007/S10853-017-0905-0 |
0.465 |
|
| 2016 |
Dannoon S, Ganguly T, Cahaya H, Geruntho JJ, Galliher MS, Beyer SK, Choy CJ, Hopkins MR, Regan M, Blecha JE, Skultetyova L, Drake CR, Jivan S, Barinka C, Jones EF, ... Berkman CE, et al. Structure-Activity Relationship of 18F-labeled phosphoramidate peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-targeted inhibitor analogues for PET imaging of prostate cancer. Journal of Medicinal Chemistry. PMID 27228467 DOI: 10.1021/Acs.Jmedchem.5B01850 |
0.449 |
|
| 2016 |
Choy CJ, Berkman CE. A method to determine the mode of binding for GCPII inhibitors using bio-layer interferometry. Journal of Enzyme Inhibition and Medicinal Chemistry. 1-4. PMID 26873576 DOI: 10.3109/14756366.2015.1132208 |
0.319 |
|
| 2016 |
Whalley E, Berkman C, Vanbrocklin H, Langton-Webster B. Development and safety of a novel, irreversibly-binding PSMA-targeted prostate cancer radiodiagnostic. Journal of Clinical Oncology. 34: 11568-11568. DOI: 10.1200/Jco.2016.34.15_Suppl.11568 |
0.453 |
|
| 2015 |
Nedrow JR, Latoche JD, Day KE, Modi J, Ganguly T, Zeng D, Kurland BF, Berkman CE, Anderson CJ. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 26552656 DOI: 10.1007/S11307-015-0908-7 |
0.44 |
|
| 2015 |
Novakova Z, Cerny J, Choy CJ, Nedrow J, Choi JK, Lubkowski J, Berkman CE, Barinka C. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities. The Febs Journal. PMID 26460595 DOI: 10.1111/Febs.13557 |
0.326 |
|
| 2015 |
Ganguly T, Dannoon S, Hopkins MR, Murphy S, Cahaya H, Blecha JE, Jivan S, Drake CR, Barinka C, Jones EF, VanBrocklin HF, Berkman CE. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nuclear Medicine and Biology. PMID 26169882 DOI: 10.1016/J.Nucmedbio.2015.06.003 |
0.459 |
|
| 2015 |
Ley CR, Beattie NR, Dannoon S, Regan M, VanBrocklin H, Berkman CE. Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry Letters. 25: 2536-9. PMID 25956413 DOI: 10.1016/J.Bmcl.2015.04.047 |
0.492 |
|
| 2014 |
Martin SE, Ganguly T, Munske GR, Fulton MD, Hopkins MR, Berkman CE, Black ME. Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer. Bioconjugate Chemistry. 25: 1752-60. PMID 25157916 DOI: 10.1021/Bc500362N |
0.46 |
|
| 2014 |
Wu LY, Johnson JM, Simmons JK, Mendes DE, Geruntho JJ, Liu T, Dirksen WP, Rosol TJ, Davis WC, Berkman CE. Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells. The Prostate. 74: 451-7. PMID 24449207 DOI: 10.1002/Pros.22727 |
0.474 |
|
| 2014 |
Liu T, Mendes DE, Berkman CE. Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells. International Journal of Oncology. 44: 918-22. PMID 24424840 DOI: 10.3892/Ijo.2014.2256 |
0.46 |
|
| 2014 |
Liu T, Mendes DE, Berkman CE. Prolonged androgen deprivation leads to overexpression of calpain 2: implications for prostate cancer progression. International Journal of Oncology. 44: 467-72. PMID 24297527 DOI: 10.3892/Ijo.2013.2196 |
0.453 |
|
| 2014 |
Wu LY, Bansal N, Liu T, Berkman CE, Bertino JR. Abstract 214: Androgen resistance in prostate cancer is associated with an enrichment of stem-like cells Cancer Research. 74: 214-214. DOI: 10.1158/1538-7445.Am2014-214 |
0.363 |
|
| 2013 |
Liu T, Mendes DE, Berkman CE. From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells. International Journal of Oncology. 43: 1125-30. PMID 23877345 DOI: 10.3892/Ijo.2013.2020 |
0.408 |
|
| 2013 |
Choy CJ, Fulton MD, Davis AL, Hopkins M, Choi JK, Anderson MO, Berkman CE. Rationally designed sulfamides as glutamate carboxypeptidase II inhibitors. Chemical Biology & Drug Design. 82: 612-9. PMID 23773397 DOI: 10.1111/Cbdd.12174 |
0.389 |
|
| 2013 |
Kasten BB, Liu T, Nedrow-Byers JR, Benny PD, Berkman CE. Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorganic & Medicinal Chemistry Letters. 23: 565-8. PMID 23232055 DOI: 10.1016/J.Bmcl.2012.11.015 |
0.456 |
|
| 2013 |
Nedrow-Byers JR, Moore AL, Ganguly T, Hopkins MR, Fulton MD, Benny PD, Berkman CE. PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. The Prostate. 73: 355-62. PMID 22911263 DOI: 10.1002/Pros.22575 |
0.407 |
|
| 2012 |
Liu T, Wu LY, Fulton MD, Johnson JM, Berkman CE. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. International Journal of Oncology. 41: 2087-92. PMID 23041906 DOI: 10.3892/Ijo.2012.1649 |
0.452 |
|
| 2012 |
Nedrow-Byers JR, Jabbes M, Jewett C, Ganguly T, He H, Liu T, Benny P, Bryan JN, Berkman CE. A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. The Prostate. 72: 904-12. PMID 22670265 DOI: 10.1002/Pros.21493 |
0.469 |
|
| 2012 |
Liu T, Nedrow-Byers JR, Hopkins MR, Wu LY, Lee J, Reilly PT, Berkman CE. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. Bioorganic & Medicinal Chemistry Letters. 22: 3931-4. PMID 22607680 DOI: 10.1016/J.Bmcl.2012.04.110 |
0.499 |
|
| 2012 |
Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE. Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. The Prostate. 72: 1532-41. PMID 22488169 DOI: 10.1002/Pros.22508 |
0.453 |
|
| 2012 |
Wu LY, Abernathy DE, Liu T, Van Wie BJ, Davis WC, Berkman CE. Abstract C40: Large-scale isolation of prostate cancer cells by combining leukapheresis and elutriation with chemoaffinity capture Cancer Research. 72: C40-C40. DOI: 10.1158/1538-7445.Prca2012-C40 |
0.453 |
|
| 2012 |
Wu LY, Liu T, Vanwie B, Davis WC, Berkman CE. Abstract A20: Molecular Detection of Prostate-Specific Membrane Antigen in Canine Prostate Carcinoma Cells Cancer Research. 72. DOI: 10.1158/1538-7445.Csb12-A20 |
0.462 |
|
| 2011 |
Liu T, Nedrow-Byers JR, Hopkins MR, Berkman CE. Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen. Bioorganic & Medicinal Chemistry Letters. 21: 7013-6. PMID 22018464 DOI: 10.1016/J.Bmcl.2011.09.115 |
0.474 |
|
| 2011 |
Liu T, Jabbes M, Nedrow-Byers JR, Wu LY, Bryan JN, Berkman CE. Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium. International Journal of Oncology. 38: 1349-55. PMID 21331445 DOI: 10.3892/Ijo.2011.946 |
0.412 |
|
| 2011 |
Blank BR, Alayoglu P, Engen W, Choi JK, Berkman CE, Anderson MO. N-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2). Chemical Biology & Drug Design. 77: 241-7. PMID 21219587 DOI: 10.1111/J.1747-0285.2011.01085.X |
0.436 |
|
| 2011 |
Wu LY, Liu T, Grimm AL, Davis WC, Berkman CE. Flow cytometric detection of prostate tumor cells using chemoaffinity labels. The Prostate. 71: 52-61. PMID 20632319 DOI: 10.1002/Pros.21221 |
0.41 |
|
| 2011 |
Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE. Abstract A53: Prostate cancer cell capture using immobilized inhibitors of prostate-specific membrane antigen. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A53 |
0.47 |
|
| 2011 |
Liu T, Nedrow-Byers JR, Hopkins MR, Wu LY, Lee J, Reilly PTA, Berkman CE. Abstract A117: Rapid uptake of a streptavidin conjugate into prostate cancer cells: A model of macromolecule targeting delivery. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A117 |
0.505 |
|
| 2010 |
Liu T, Wu LY, Hopkins MR, Choi JK, Berkman CE. A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorganic & Medicinal Chemistry Letters. 20: 7124-6. PMID 20947349 DOI: 10.1016/J.Bmcl.2010.09.057 |
0.462 |
|
| 2010 |
Liu T, Wu LY, Berkman CE. Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Letters. 296: 106-12. PMID 20452720 DOI: 10.1016/J.Canlet.2010.04.003 |
0.43 |
|
| 2010 |
Liu T, Wu LY, Choi JK, Berkman CE. Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. International Journal of Oncology. 36: 777-84. PMID 20198319 DOI: 10.3892/Ijo_00000553 |
0.462 |
|
| 2010 |
Yao V, Berkman CE, Choi JK, O'Keefe DS, Bacich DJ. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. The Prostate. 70: 305-16. PMID 19830782 DOI: 10.1002/Pros.21065 |
0.475 |
|
| 2010 |
Wu LY, Choi JK, Hatton KY, Berkman CE. A simple method for the oxidation of α-amino acid esters to α-oximino esters Tetrahedron Letters. 51: 402-403. DOI: 10.1016/J.Tetlet.2009.11.045 |
0.34 |
|
| 2009 |
Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu T, Vejdani K, VanBrocklin HF, Berkman CE, Jones EF. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 2042-8. PMID 19910433 DOI: 10.2967/Jnumed.109.066589 |
0.447 |
|
| 2009 |
Liu T, Wu LY, Choi JK, Berkman CE. In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen. The Prostate. 69: 585-94. PMID 19142895 DOI: 10.1002/Pros.20909 |
0.477 |
|
| 2009 |
Liu T, Wu LY, Berkman CE. Abstract A136: Lysosome‐targeted photodynamic therapy for prostate cancer cells with a pyropheophorbide‐α conjugated inhibitor of prostate‐specific membrane antigen Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A136 |
0.462 |
|
| 2008 |
Liu T, Toriyabe Y, Kazak M, Berkman CE. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry. 47: 12658-60. PMID 18983168 DOI: 10.1021/Bi801883V |
0.455 |
|
| 2008 |
Liu T, Wu LY, Kazak M, Berkman CE. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. The Prostate. 68: 955-64. PMID 18361407 DOI: 10.1002/Pros.20753 |
0.471 |
|
| 2008 |
Wu LY, Do JC, Kazak M, Page H, Toriyabe Y, Anderson MO, Berkman CE. Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry Letters. 18: 281-4. PMID 18023582 DOI: 10.1016/J.Bmcl.2007.10.096 |
0.487 |
|
| 2007 |
Wu LY, Anderson MO, Toriyabe Y, Maung J, Campbell TY, Tajon C, Kazak M, Moser J, Berkman CE. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry. 15: 7434-43. PMID 17869524 DOI: 10.1016/J.Bmc.2007.07.028 |
0.428 |
|
| 2007 |
Anderson MO, Wu LY, Santiago NM, Moser JM, Rowley JA, Bolstad ES, Berkman CE. Substrate specificity of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry. 15: 6678-86. PMID 17764959 DOI: 10.1016/J.Bmc.2007.08.006 |
0.376 |
|
| 2007 |
Blecha JE, Anderson MO, Chow JM, Guevarra CC, Pender C, Penaranda C, Zavodovskaya M, Youngren JF, Berkman CE. Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs. Bioorganic & Medicinal Chemistry Letters. 17: 4026-9. PMID 17502145 DOI: 10.1016/J.Bmcl.2007.04.092 |
0.334 |
|
| 2006 |
Liu T, Toriyabe Y, Berkman CE. Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expression and Purification. 49: 251-5. PMID 16815035 DOI: 10.1016/J.Pep.2006.05.008 |
0.435 |
|
| 2006 |
Wone DW, Rowley JA, Garofalo AW, Berkman CE. Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry. 14: 67-76. PMID 16154750 DOI: 10.1016/J.Bmc.2005.07.056 |
0.439 |
|
| 2004 |
Mallari JP, Choy CJ, Hu Y, Martinez AR, Hosaka M, Toriyabe Y, Maung J, Blecha JE, Pavkovic SF, Berkman CE. Stereoselective inhibition of glutamate carboxypeptidase by organophosphorus derivatives of glutamic acid. Bioorganic & Medicinal Chemistry. 12: 6011-20. PMID 15498677 DOI: 10.1016/J.Bmc.2004.08.016 |
0.319 |
|
| 2004 |
Maung J, Mallari JP, Girtsman TA, Wu LY, Rowley JA, Santiago NM, Brunelle AN, Berkman CE. Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorganic & Medicinal Chemistry. 12: 4969-79. PMID 15336276 DOI: 10.1016/J.Bmc.2004.06.031 |
0.407 |
|
| 2003 |
Lu H, Ng RJ, Shieh CC, Martinez AR, Berkman CE. Inhibition of glutamate carboxypeptidase by phosphoryl and thiophosphoryl derivatives of glutamic and 2-hydroxyglutaric acid Phosphorus, Sulfur and Silicon and the Related Elements. 178: 17-32. DOI: 10.1080/10426500307817 |
0.314 |
|
| 2002 |
Kamga I, Ng R, Hosaka M, Berkman CE. High-performance liquid chromatography method for detecting prostate-specific membrane antigen activity. Analytical Biochemistry. 310: 125-7. PMID 12413483 DOI: 10.1016/S0003-2697(02)00284-1 |
0.39 |
|
| 2001 |
Rodriguez CE, Lu H, Martinez AR, Hu Y, Brunelle A, Berkman CE. Inhibition of glutamate carboxypeptidase II by phosphonamidothionate derivatives of glutamic acid. Journal of Enzyme Inhibition. 16: 359-65. PMID 11916141 DOI: 10.1080/14756360109162384 |
0.345 |
|
| 2001 |
Lu H, Berkman CE. Stereoselective inhibition of glutamate carboxypeptidase by chiral phosphonothioic acids. Bioorganic & Medicinal Chemistry. 9: 395-402. PMID 11249132 DOI: 10.1016/S0968-0896(00)00254-6 |
0.344 |
|
| 1999 |
Myers RS, Paton PT, Dastgah A, Martell JR, Berkman CE. A general high-performance liquid chromatography-based assay for the hydrolysis of N-acyl glutamates. Analytical Biochemistry. 275: 187-91. PMID 10552903 DOI: 10.1006/Abio.1999.4327 |
0.317 |
|
| 1999 |
Rodriguez CE, Lu H, Dinh TT, Mlodnosky KL, Dastgah A, Lam VQ, Nichols CB, Berkman CE. Competitive inhibition of a glutamate carboxypeptidase by phosphonamidothionate derivatives of glutamic acid. Bioorganic & Medicinal Chemistry Letters. 9: 1415-8. PMID 10360747 DOI: 10.1016/S0960-894X(99)00198-5 |
0.318 |
|
| 1998 |
Rodriguez CE, Holmes HM, Mlodnosky KL, Lam VQ, Berkman CE. Evaluation of phosphorus-containing inhibitors of gamma-glutamyl hydrolase. Bioorganic & Medicinal Chemistry Letters. 8: 1521-4. PMID 9873382 DOI: 10.1016/S0960-894X(98)00253-4 |
0.33 |
|
| 1992 |
Thompson CM, Ryu S, Berkman CE. Consequence of phosphorus stereochemistry upon the postinhibitory reaction kinetics of acetylcholinesterase poisoned by phosphorothiolates Journal of the American Chemical Society. 114: 10710-10715. DOI: 10.1021/Ja00053A005 |
0.303 |
|
| Show low-probability matches. |